Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGXT | P21549 | 1/20 | 0.57 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.49 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 7/20 | 0.43 |
| ▸ | HTR2B | P41595 | 7/20 | 0.43 |
| ▸ | DRD2 | P14416 | 3/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL120103 | 0.80 | AGXT (0.55) | AGXTLOXL2ADAMTS4HTR1AHTR2B | |
| SCHEMBL13960026 | 0.79 | KMT2A (0.57) | AGXTLOXL2ADAMTS4HTR1AHTR2B | |
| SCHEMBL119892 | 0.79 | AGXT (0.54) | AGXTLOXL2ADAMTS4HTR1AHTR2B | |
| SCHEMBL14153179 | 0.78 | RAB9A (0.57) | AGXTLOXL2ADAMTS4HTR1AHTR2B | |
| SCHEMBL5758322 | 0.77 | AGXT (0.55) | AGXTLOXL2ADAMTS4HTR1AHTR2B | |
| SCHEMBL9043542 | 0.75 | PTPRC (0.57) | AGXTADAMTS4 | |
| SCHEMBL14145540 | 0.73 | AGXT (0.68) | AGXTLOXL2HTR1AHTR2BDRD2 | |
| SCHEMBL1520921 | 0.73 | AGXT (1.00) | AGXTLOXL2HTR1AHTR2BDRD2 | |
| SCHEMBL1655663 | 0.73 | LPL (0.49) | AGXTLOXL2ADAMTS4HTR1AHTR2B | |
| SCHEMBL1746605 | 0.73 | FFAR1 (0.60) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6608104-B2 | Antiarthritic agents; anticancer agents | PFIZER INC | 2003-08-19 | — | — | US | claimed |
| US-20020019534-A1 | Gem substituted hydroxamic acids | PFIZER INC. | 2002-02-14 | — | — | US | claimed |
| CN-102458394-A | Treatment or prevention of proliferative conditions | UNIV DUNDEE | 2012-05-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019534-A1 | Gem substituted hydroxamic acids | MMP14, TOP2A, ADAMTS1 | AGXT 107/4885LOXL2 1604/4885ADAMTS4 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.